Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011

Although recent FDA approvals on ipilimumab and sipuleucel-T represent major milestones, the ultimate success of immunotherapy approaches will likely benefit from appropriate combinations with other immunotherapeutic and/or non-immunotherapeutic approaches. However, implementation of ideal combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Forero, Ivan Martinez, Okada, Hideho, Topalian, Suzanne L, Gajewski, Thomas F, Korman, Alan J, Melero, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404934/
https://www.ncbi.nlm.nih.gov/pubmed/22640522
http://dx.doi.org/10.1186/1479-5876-10-108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404934/
https://www.ncbi.nlm.nih.gov/pubmed/22640522
http://dx.doi.org/10.1186/1479-5876-10-108

Ejemplares similares